图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
真核基因表达评论综述™
影响因子: 1.734 5年影响因子: 1.848 SJR: 0.627 SNIP: 0.516 CiteScore™: 1.96

ISSN 打印: 1045-4403
ISSN 在线: 2162-6502

真核基因表达评论综述™

DOI: 10.1615/CritRevEukaryotGeneExpr.2013006875
pages 15-28

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

Julio Morales
Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75399
Longshan Li
Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75399
Farjana J. Fattah
Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75399
Ying Dong
Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75399
Erik A. Bey
Department of Basic Pharmaceutical Sciences & Mary Bapp Randolph, West Virginia University, Morgantown, WV 26506
Malina Patel
Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75399
Jinming Gao
Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75399
David A. Boothman
Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75399

ABSTRACT

Poly (ADP-ribose) polymerases (PARPs) are a family of related enzymes that share the ability to catalyze the transfer of ADP-ribose to target proteins. PARPs play an important role in various cellular processes, including modulation of chromatin structure, transcription, replication, recombination, and DNA repair. The role of PARP proteins in DNA repair is of particular interest, in view of the finding that certain tumors defective in homologous recombination mechanisms, may rely on PARP-mediated DNA repair for survival, and are sensitive to its inhibition. PARP inhibitors may also increase tumor sensitivity to DNA-damaging agents. Clinical trials of PARP inhibitors are investigating the utility of these approaches in cancer. The hyperactivation of PARP has also been shown to result in a specific programmed cell death pathway involving NAD+/ATP depletion, mu-calpain activation, loss of mitochondrial membrane potential, and the release of apoptosis inducing factor. Hyperactivation of the PARP pathway may be exploited to selectively kill cancer cells. Other PARP forms, including tankyrase 1 (PARP 5a), which plays an important role in enhancing telomere elongation by telomerase, have been found to be potential targets in cancer therapy. The PARP pathway and its inhibition thus offers a number of opportunities for therapeutic intervention in both cancer and other disease states.


Articles with similar content:

Targeting the Regulatory Machinery of BIM for Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Steven Grant, Hisashi Harada

Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Niranjali Devaraj, Venugopal Vinod Prabhu

A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Yuhao Wang, Benjamin Bonavida

Mechanisms of p53-Mediated Apoptosis
Critical Reviews™ in Oncogenesis, Vol.9, 1998, issue 1
Han-Fei Ding, David E. Fisher

Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Ali Sharif, Wafa Majeed, Bushra Akhtar, Muhammad Furqan Akhtar, Faqir Muhammad